Pancreatic Cancer Research

ResearcherBeth Israel Deaconess Medical CenterActive in the last 2 years

Cullen M. Taniguchi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8052-3316; OpenAlex author ID A5079075847; NIH RePORTER profile ID 12526892. Sources: ClinicalTrials.gov.

Their work

Papers
37 (first author 1, last author 16)
Trials
1 (principal investigator on 1)
Grants
2
Labs led
1
Collaborators
115
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 4 papers · 2019: 7 papers, 1 trial · 2020: 5 papers · 2021: 7 papers · 2022: 7 papers · 2023: 2 papers, 1 grant · 2024: 3 papers · 2025: none · 2026: 1 grant

Papers 37

  1. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Co-author DOI 10.1002/cam4.7434↗
  2. UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect. First author DOI 10.1007/s10555-023-10157-4↗
  3. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II T… Co-author DOI 10.1200/jco.24.00081↗
  4. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
  5. Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers15225355↗
  6. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Co-author DOI 10.1016/j.ctro.2021.12.012↗
  7. Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. Co-author DOI 10.1016/j.ctro.2022.04.007↗
  8. Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2022.04.044↗
  9. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  10. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. Last author DOI 10.1053/j.gastro.2022.02.024↗
  11. Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model. Last author DOI 10.1186/s12885-022-09255-3↗
  12. The Therapeutic Potential of FLASH-RT for Pancreatic Cancer. Last author DOI 10.3390/cancers14051167↗
  13. Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Last author DOI 10.1016/j.adro.2020.11.006↗
  14. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Last author DOI 10.1016/j.adro.2021.100763↗
  15. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite … Co-author DOI 10.1016/j.ctro.2021.02.004↗
  16. APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Co-author DOI 10.1038/s43018-021-00268-8↗
  17. ADAM10 Evens Out the Double-Edged Sword of Radiotherapy in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-21-0519↗
  18. Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. Co-author DOI 10.1158/1078-0432.ccr-20-3925↗
  19. Comparative Untargeted Metabolomic Profiling of Induced Mitochondrial Fusion in Pancreatic Cancer. Last author DOI 10.3390/metabo11090627↗
  20. Resolving the HIF paradox in pancreatic cancer. Last author DOI 10.1016/j.canlet.2020.05.033↗
  21. Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. Last author DOI 10.1016/j.currproblcancer.2020.100607↗
  22. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic… Last author DOI 10.1016/j.ijrobp.2020.09.022↗
  23. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Co-author DOI 10.1016/j.prro.2020.01.012↗
  24. Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. Last author DOI 10.3390/cancers12092487↗
  25. Fasting Reduces Intestinal Radiotoxicity, Enabling Dose-Escalated Radiation Therapy for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2019.06.2533↗
  26. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. Co-author DOI 10.1016/j.vgie.2019.02.009↗
  27. EUS-guided placement of fiducial markers for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.vgie.2019.05.007↗
  28. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2018.09.022↗
  29. Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-18-1785↗
  30. Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progre… Co-author DOI 10.1158/1078-0432.ccr-18-1955↗
  31. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. Last author DOI 10.1172/jci.insight.126915↗
  32. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therap… Co-author DOI 10.1002/cncr.31251↗
  33. Dose escalation for locally advanced pancreatic cancer: How high can we go? Last author DOI 10.1016/j.adro.2018.07.008↗
  34. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-3668↗
  35. Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism Last author DOI 10.2139/ssrn.3188491↗
  36. EGLN Inhibition Reduces Gastrointestinal Radiation Toxicity and Improves Survival in a Murine Model of Locally Advanced Pancreatic Cancer Last author DOI 10.1101/195610↗
  37. Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2012.07.2366↗

Trials 1

  1. A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer Principal investigator NCT04193904↗

Grants 2

  1. The Role of HIF2 in Pancreatic Ductal Adenocarcinoma R01CA269565↗
  2. Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer R01CA227517↗

Closest collaborators

The 25 strongest of 115 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Albert C. Koong · 14 shared papers, 2 shared grants, 2013–2026 · strength 3.56
  2. Eugene Jon Koay · 20 shared papers, 2018–2024 · strength 2.05
  3. Matthew H. G. Katz · 13 shared papers, 2018–2024 · strength 1.29
  4. Joseph M. Herman · 13 shared papers, 2018–2023 · strength 1.26
  5. Ethan Bernard Ludmir · 9 shared papers, 2020–2024 · strength 1.15
  6. Joseph Abi Jaoude · 8 shared papers, 2020–2023 · strength 1.08
  7. Daniel Lin · 10 shared papers, 2018–2022 · strength 1.05
  8. Anirban Maitra · 12 shared papers, 2018–2022 · strength 1.04
  9. Manoop S. Bhutani · 9 shared papers, 2019–2023 · strength 0.99
  10. Grace L. Smith · 7 shared papers, 2021–2024 · strength 0.89
  11. Robert A. Wolff · 9 shared papers, 2018–2024 · strength 0.87
  12. Nicholas D. Nguyen · 7 shared papers, 2019–2022 · strength 0.78
  13. Ching-Wei David Tzeng · 7 shared papers, 2019–2024 · strength 0.74
  14. Tara N. Fujimoto · 7 shared papers, 2017–2022 · strength 0.65
  15. Shalini Moningi · 6 shared papers, 2018–2023 · strength 0.63
  16. Ramez Kouzy · 5 shared papers, 2020–2024 · strength 0.61
  17. Michael P. Kim · 6 shared papers, 2018–2024 · strength 0.60
  18. Carolina J. García García · 4 shared papers, 2021–2022 · strength 0.59
  19. Emily G. Caggiano · 2 shared papers, 2022–2024 · strength 0.57
  20. Meifang Yu · 6 shared papers, 2018–2022 · strength 0.57
  21. Shubham Pant · 5 shared papers, 2019–2024 · strength 0.53
  22. Vincent Bernard · 5 shared papers, 2019–2023 · strength 0.50
  23. Irina Mihaela Cazacu · 4 shared papers, 2019–2023 · strength 0.44
  24. Christopher H. Crane · 5 shared papers, 2018–2022 · strength 0.44
  25. Lauren Elizabeth Colbert · 5 shared papers, 2017–2023 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.